Multifocal motor neuropathy improved by IVIg

Piera Federico, Douglas W. Zochodne, Angelika F. Hahn, +2

Neurology

Paclitaxel in Pretreated Metastatic Penile Cancer: Final Results of a Phase 2 Study

Giuseppe Di Lorenzo, Piera Federico, Carlo Buonerba, +13

European Urology

UrologySurgical OncologyGenitourinary CancerMedicineCancer Treatment +5

Cisplatin and 5‐fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis

Giuseppe Di Lorenzo, Carlo Buonerba, Piera Federico, +12

British Journal of Urology

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, +225

The Lancet Oncology

Endocrine OncologyBreast OncologyMedicinePharmacologyEndocrine-sensitive Breast Cancer +5

Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma

Giuseppe Di Lorenzo, Carlo Buonerba, Piera Federico, +13

European Urology

Third-line SorafenibUrologyOncologyMtor InhibitorsGenitourinary Cancer +5

Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)

Giovannella Palmieri, G. Merola, Piera Federico, +11

Annals of Oncology

Genitourinary CancerMedicinePreliminary ResultsPathologyPhase Ii Study +5

Imatinib mesylate in thymic epithelial malignancies

Giovannella Palmieri, Mirella Marino, Carlo Buonerba, +13

Cancer Chemotherapy and Pharmacology

PathologyMedicineMalignant DiseaseImatinib MesylateTumor Biology

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Francesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, +22

Liver Cancer

Capecitabine Plus Gemcitabine in Thymic Epithelial Tumors: Final Analysis of a Phase II Trial

Giovannella Palmieri, Carlo Buonerba, Margaret Ottaviano, +12

Future Oncology

Potential Value of Gleason Score in Predicting the Benefit of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Carlo Buonerba, Gregory R. Pond, Guru Sonpavde, +14

Future Oncology